NATAP http://natap.org/
_______________________________________________


Pfizer and Monogram Will Make HIV Co-receptor Tropism Test Available Globally

Pfizer Inc and Monogram Biosciences, Inc. announced today a non-exclusive collaboration to make Monogram’s HIV Co-Receptor Tropism Assay available for patient use on a global basis. The assay is a diagnostic tool to show tropism –the path taken by the virus to access human CD4 cells.

Tropism information is intended to help identify patients who are most likely to respond to a class of investigational drugs known as CCR5 Antagonists.

CCR5 antagonists are designed to block viral cell entry through the CCR5 co-receptor. Studies have shown that 80-85 percent of people newly diagnosed with HIV and previously untreated with HIV therapy have dominant CCR5-tropic virus. This drops to 50-60 percent in patients who have been treated before with antiretroviral medicines.


_______________________________________________
NATAP nataphcvhiv mailing list -- nataphcvhiv@...